As­traZeneca reshuf­fles Chi­na lead­er­ship, sets up bio­phar­ma group to mir­ror glob­al struc­ture

As­traZeneca’s Chi­na group has reshuf­fled its lead­er­ship and set up a new bio­phar­ma group fol­low­ing the de­par­ture of its gen­er­al man­ag­er in on­col­o­gy, ac­cord­ing to re­ports in Chi­nese me­dia.

Justin Chin, a nine-year vet­er­an of the drug­mak­er who most re­cent­ly led the on­col­o­gy busi­ness in Chi­na, is re­turn­ing to Sin­ga­pore for fam­i­ly rea­sons, sev­er­al out­lets re­port­ed, cit­ing an in­ter­nal an­nounce­ment. Chi­na gen­er­al man­ag­er Michael Lai will fill his role, while Alex Lin — who’s al­ready in charge of res­pi­ra­to­ry, bi­o­log­ics as well as Hong Kong and Macau — will lead the new­ly-es­tab­lished bio­phar­ma unit.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.